FDA
-
-
-
-
-
-
-
Theratechnologies Announces All U.S. Oncology Clinical Sites Now Enrolling for Phase 1 Trial of Sudocetaxel Zendusortide
-
-
-
-
-
-
-
Theratechnologies to Present Preclinical Data at AACR Demonstrating Synergy Between TH1902 and Anti-PD-L1 Immunotherapy in Cold Tumor Model
-
-
-
-
-
-
-
Theratechnologies Reports Financial Results for the Third Quarter of Fiscal 2022 and Provides Business Update
-
-
-
-
-
-
-
Theratechnologies Announces New Head of Investor Relations
-
-
-
-
-
-
-
Theratechnologies Strengthens Global Commercial Capabilities by Launching Internal Field Force
-
-
-
-
-
-
-
Theratechnologies Announces Publication of TH1902 Preclinical Data in Peer-Reviewed Journal, Cancer Science
-
-
-
-
-
-
-
Theratechnologies annonce l’administration du TH1902 au premier patient dans l’essai clinique de phase 1 pour le traitement des tumeurs solides exprimant le récepteur de la sortiline
-
322,260 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

